Official AMFI data
Arthkar — Understand Money, Invest Smartly
Aditya Birla Sun Life

Aditya Birla Sun Life Pharma And Healthcare Fund

Sectoral / ThematicEquityVery High risk Rank 29 of 157

NAV · Direct-Growth

₹40.65-0.19-0.47%

As of 17 Aug 2026 · AMFI

NAV growth+16.8%
Aug ’25Aug ’26
Arthkar verdictSolid on the numbers

Returns

Beats category

1Y, 3Y, 5Y all ahead

Cost

Average

0.84% vs NaN% peers

Volatility

Below average

15.3% vs 16.3% cat (3Y)

Consistency

Steady

positive in 5 of 7 years

Beats its Sectoral / Thematic category on 1Y, 3Y & 5Y — and has been steadier than peers.

1Y return

+17.0%

+6.0 vs cat

3Y CAGR

+22.2%

+5.1 vs cat

5Y CAGR

+14.8%

+0.0 vs cat

AUM

₹950.31 Cr

fund size

Expense

0.84%

direct plan

Volatility 3Y

15.3%

▼ vs 16.3%

Go deeper on Aditya Birla Sun Life Pharma And Healthcare Fund

Two data-only views, computed from this fund's real NAV history — no projections.

In plain English

Aditya Birla Sun Life Pharma and Healthcare Fund is a Sectoral / Thematic scheme from Aditya Birla Sun Life. The portfolio is ~97% in equities. Long-run track record: about 14.8% CAGR over 5 years. Volatility is typical for equity — 20–30 % drawdowns happen during market stress. Worst historical drawdown: -20% in Jun 2022, recovered in 13 months. Wrong fit if you need this money in less than 7 years.

Auto-generated from holdings, returns and risk data. No paid placement, no copy-pasted boilerplate.

NAV history

Showing Direct · Growth · INF209KB1O25

NAV (Direct-Growth)

₹40.6500

Last 1Y

+16.81%

Aug 25Min ₹32.36 · Max ₹41.02 · 246 ptsAug 26

Drawdown stories

The crashes you should know about — and how long the fund took to recover.

Jun 2022

-20.5%

Peak ₹20.97 on 16 Sept 2021 → trough ₹16.68 on 17 Jun 2022 (9 months down).

Recovered in 13 months· 20 Jul 2023

Mar 2020

-20.3%

Peak ₹11.81 on 13 Feb 2020 → trough ₹9.41 on 23 Mar 2020 (1 months down).

Recovered in 1 months· 9 Apr 2020

Feb 2025

-15.9%

Peak ₹35.59 on 9 Oct 2024 → trough ₹29.92 on 28 Feb 2025 (5 months down).

Recovered in 14 months· 5 May 2026

Mar 2021

-10.1%

Peak ₹17.56 on 11 Jan 2021 → trough ₹15.79 on 18 Mar 2021 (2 months down).

Recovered in 1 months· 9 Apr 2021

Computed from the full NAV history. We show drawdowns deeper than 10%, sorted by depth.

Honesty score

A 1–5 grade on the dimensions other sites won't surface — expense bloat, AUM bloat, concentration, mandate compliance.

4

Honesty score

4 / 5

Solid scheme on the dimensions we check. No red flags.

  • Expense ratio

    0.84% — typical for category.

  • AUM size

    ₹950 Cr.

  • Sector concentration

    Top 3 sectors = 98.6% — heavy concentration risk.

Computed from expense ratio, AUM, sector concentration and SEBI mandate compliance. No paid review.

Performance

Returns for various periods, with category average and peer rank.

PeriodReturnsCategory avgRank
1W-0.47%-0.21%170/ 286
1M+2.94%+2.68%138/ 286
3M+9.13%+7.72%91/ 286
6M+19.07%+7.00%22/ 277
YTD+19.98%+6.23%19/ 273
1Y+17.01%+10.98%56/ 258
2Y+10.04%+5.93%42/ 203
3Y+22.25%+17.18%29/ 157
5Y+14.82%+14.80%58/ 125
7Y+22.15%+18.94%30/ 104

Portfolio composition

Asset allocation

  • Equity96.83%
  • Cash3.17%

By market cap

  • Large cap31.36%
  • Mid cap26.52%
  • Small cap29.36%
  • Others12.76%

Concentration

Holdings

40

Avg market cap

₹54.5K Cr

Top 10 stocks

53.78%

Top 5 stocks

34.33%

Top 3 sectors

98.61%

Top holdings

Top 15 positions by weight, latest disclosure.

#InstrumentSectorWeight
  • 1

    Sun Pharmaceuticals Industries Ltd

    13.42%
  • 1

    Sun Pharmaceuticals Industries Ltd

    13.17%
  • 2

    Apollo Hospitals Enterprise Ltd

    7.34%
  • 2

    Apollo Hospitals Enterprise Ltd

    7.20%
  • 3

    Torrent Pharmaceuticals Ltd

    5.03%
  • 4

    J.B. Chemicals & Pharmaceuticals Ltd

    4.99%
  • 3

    Torrent Pharmaceuticals Ltd

    4.76%
  • 4

    J.B. Chemicals & Pharmaceuticals Ltd

    4.71%
  • 5

    Aurobindo Pharma Ltd

    4.49%
  • 5

    Aurobindo Pharma Ltd

    4.42%
  • 6

    Ajanta Pharma Ltd

    4.22%
  • 7

    Lupin Ltd

    4.21%
  • 8

    Ipca Laboratories Ltd

    4.11%
  • 6

    Ajanta Pharma Ltd

    4.05%
  • 7

    Lupin Ltd

    4.00%

Fundamentals (vs category)

Portfolio-weighted ratios, compared with the category average.

MetricFundCategory avgDiff
  • P/E ratio38.5541.09-2.54
  • P/B ratio5.705.83-0.13
  • Price / Sales5.505.71-0.21
  • Price / Cash Flow29.8230.54-0.72
  • Dividend yield0.81%0.63%+0.18
  • Return on equity (ROE)18.87%16.57%+2.30

Risk metrics

Standard deviation, Sharpe, Sortino, Beta — all vs category average.

Metric1Y3Y5YCat 1YCat 3YCat 5Y
  • Standard deviation

    Volatility — lower means steadier returns.

    15.8515.7115.2214.9216.2915.44
  • Sharpe ratio

    Risk-adjusted return — higher is better.

    0.731.060.610.480.980.58
  • Sortino ratio

    Like Sharpe but only counts downside volatility.

    1.321.961.010.831.710.94
  • Beta

    1 = moves with the market. <1 = less volatile.

    0.770.920.930.940.950.94

Peers in Sectoral / Thematic

Other schemes in the same SEBI category, ranked by AUM.

Available plans & options

PlanOptionFull nameISIN

Click a plan to see its NAV and chart above. Direct plans have lower expense ratios than Regular — same portfolio, more of the return stays with you.